exp date isn't null, but text field is
Advanced hormone-niaive prostate cancer with at least one of the following:
Initially 240mg as two 120mg injections, then 80mg every 28 days.
Consider changing to 3-monthly LHRH agonist with anti-androgen cover.
No dose adjustment required for the elderly or patients with mild to moderate hepatic or renal impairment. Patients with severe hepatic or renal impairment have not been studied.
Degarelix is administered as a subcutaneous injection in the abdominal region.
As with other medicinal products administered by subcutaneous injection, the injection site should vary periodically.
Give injections in areas where the patient will not be exposed to pressure, eg not close to waistband or belt and not close to the ribs.
No formal drug-drug interaction studies have been performed.
Since androgen deprivation treatment may prolong the QTc interval, the concomitant use of degarelix with medicinal products known to prolong the QTc interval or medicinal products able to induce torsades de pointes, such as class IA (eg disopyramide) or class III (eg amiodarone, sotalol) antiarrhythmic medicinal products, methadone, cisapride, moxifloxacin, antipsychotics, etc, should be carefully evaluated.
Fatigue and dizziness are common adverse reactions that might influence the ability to drive and use machines.
Last reviewed: 31 July 2014
Next review: 31 July 2016
Approved By: Formulary Subgroup of ADTC
Reviewer Name(s): Clinical Pharmacist